AcelRx Pharmaceuticals has announced the publication of the results of a study to evaluate patient satisfaction with Zalviso (sublingual sufentanil...
AcelRX has submitted a New Drug Application (NDA) to the FDA for Zalviso (sufentanil sublingual microtablet system) for the management...
AcelRx Pharmaceuticals has announced that results from the IAP310 Phase III trial evaluating the safety and efficacy of Zalviso (sufentanil...
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the...
The Grünenthal Group announced that it has received EU marketing authorisation for Zalviso (sufentanil) 15 µg sublingual tablets for the...
AcelRx Pharmaceuticals announced the publication of an analysis of the pharmacokinetic characteristics of sublingually administered tablets containing Zalviso (sufentanil sublingual...
AcelRx Pharmaceuticals, Inc. has announced that the FDA has issued a Complete Response Letter (CRL) for the Company's new drug...
AcelRx Pharmaceuticals has received comments from the FDA's Division of Anesthesia, Analgesia, and Addiction Products on the Company's proposed protocol...
AcelRx Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Dzuveo (under development in the U.S. as Dsuvia) for...